Metadon Dne (Methadone Hydrochloride)

Methadone hydrochloride works as a full agonist at the mu‑opioid receptor, producing analgesic and anti‑withdrawal effects. It also blocks NMDA receptors, which may limit tolerance development. The drug’s long half‑life and high oral bioavailability support once‑daily dosing in maintenance therapy.

The appropriate dose of Metadon Dne is individualized by the prescribing clinician based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosing decisions consider factors such as severity of dependence, pain level, liver function, and potential drug interactions.

Data on methadone use in pregnancy and lactation are limited, and the drug is generally used only when the benefits outweigh potential risks. Pregnant or nursing individuals should discuss treatment options with their healthcare provider, who can assess safety and monitor both mother and child closely.

To order Metadon Dne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methadone and buprenorphine are the two most common opioid‑dependence treatments. Methadone is a full mu‑opioid agonist with a longer half‑life, offering strong suppression of cravings but requiring careful monitoring for respiratory depression. Buprenorphine is a partial agonist with a ceiling effect on respiratory depression, which may provide a safer profile for some patients.

Metadon Dne should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain potency and stability throughout its shelf life.

Metadon Dne is administered orally. The tablet (or oral formulation) should be swallowed whole with water and not chewed, crushed or dissolved unless specifically instructed by a healthcare professional. Dosing frequency is determined by the prescriber, often once daily for maintenance therapy.

The most serious risks include respiratory depression, especially when combined with other CNS depressants, and cardiac arrhythmias due to QT‑interval prolongation. Overdose can be life‑threatening. Patients should be educated to seek immediate medical attention if they experience severe breathing difficulty, fainting, or irregular heartbeats.

Metadon Dne is contraindicated in individuals with known hypersensitivity to methadone, severe respiratory insufficiency, uncontrolled cardiac arrhythmias, or those taking certain MAO inhibitors. Caution is also advised for patients with significant hepatic impairment, severe renal dysfunction, or a history of QT prolongation.